AZD0585 Phase III Long-term Study in Japan

Summary

This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .

Timeline

Start

2015-06-10

Primary completion

2017-03-11

Completion

2017-03-11

Drugs

Indications